These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Costs of congenital rubella syndrome (CRS) in Oman: evidence based on long-term follow-up of 43 children.
    Author: Al-Awaidy S, Griffiths UK, Nwar HM, Bawikar S, Al-Aisiri MS, Khandekar R, Mohammad AJ, Robertson SE.
    Journal: Vaccine; 2006 Sep 29; 24(40-41):6437-45. PubMed ID: 16814433.
    Abstract:
    As part of the national plan for elimination of rubella and congenital rubella syndrome (CRS), Oman established a national registry of CRS cases. As of May 2005, the registry included 43 surviving CRS cases, with a mean age of 11.9 years. Clinical examinations found that 84% had ocular defects, 84% had auditory/speech defects, 70% had neurological manifestations, and 42% had cardiac defects. Lifetime medical, special education, and rehabilitation costs were assessed. Using a discount rate of 3%, the average direct lifetime cost per surviving CRS patient was estimated at 18,644 US dollars. When including predicted lost productivity due to CRS, the average discounted direct and indirect lifetime costs per surviving CRS patient amounted to 98,734 US dollars.
    [Abstract] [Full Text] [Related] [New Search]